Related Experiment Video
Updated: Jan 5, 2026
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia
1Aflac Cancer & Blood Disorders Center, Emory University/Children's Healthcare of Atlanta, Atlanta, Geogia. Glen.Lew@choa.org.
Abstract:
In December 2018, the FDA approved calaspargase pegol-mknl (Asperlas, Servier Pharmaceuticals) for acute lymphoblastic leukemia (ALL) in children and young adults up to age 21. Asparaginase is a critical component in the treatment of ALL, but the niche for calaspargase within current treatment protocols is unclear.See related article by Li et al., p. 328.
More Related Videos
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
08:29Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
Published on: October 4, 2024